Combination therapy with bosentan and phosphodiesterase-5 inhibitor in pulmonary arterial hypertension

European Respiratory Journal ◽

10.1183/09031936.05.00030405 ◽

2005 ◽

Vol 26 (1) ◽

pp. 180-180 ◽

Author(s):

A. H. Morice

Keyword(s):

Pulmonary Arterial Hypertension ◽

Combination Therapy ◽

Arterial Hypertension ◽

Phosphodiesterase 5 Inhibitor ◽

Pulmonary Arterial ◽

Phosphodiesterase 5

Download Full-text

PULMONARY VASOREACTIVITY TESTING WITH ADENOSINE PREDICTS LONG TERM HEMODYNAMIC RESPONSE TO PROSTACYCLIN MONOTHERAPY, AND PROSTACYCLIN AND PHOSPHODIESTERASE-5 INHIBITOR COMBINATION THERAPY IN PULMONARY ARTERIAL HYPERTENSION

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(18)32492-6 ◽

2018 ◽

Vol 71 (11) ◽

pp. A1951

Author(s):

Ramsey Wehbe ◽

Jonathan Rich ◽

Stuart Rich

Keyword(s):

Pulmonary Arterial Hypertension ◽

Combination Therapy ◽

Arterial Hypertension ◽

Hemodynamic Response ◽

Phosphodiesterase 5 Inhibitor ◽

Pulmonary Arterial ◽

Phosphodiesterase 5 ◽

Inhibitor Combination

Download Full-text

The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension

Cardiovascular Research ◽

10.1093/cvr/cvt109 ◽

2013 ◽

Vol 99 (3) ◽

pp. 395-403 ◽

Author(s):

You-Fei Fan ◽

Rui Zhang ◽

Xin Jiang ◽

Li Wen ◽

Dan-Chen Wu ◽

...

Keyword(s):

Oxidative Stress ◽

Pulmonary Arterial Hypertension ◽

Arterial Hypertension ◽

Phosphodiesterase 5 Inhibitor ◽

Pulmonary Arterial ◽

Phosphodiesterase 5

Download Full-text

Efficacy of oral triple upfront combination therapy (long-acting prostacyclin analogue, endothelin receptor antagonist, phosphodiesterase 5 inhibitor) in the patients with idiopathic/heritable pulmonary arterial hypertension

Life Sciences ◽

10.1016/j.lfs.2013.12.168 ◽

2013 ◽

Vol 93 (25-26) ◽

pp. e48-e49

Author(s):

Takeshi Ogo ◽

Shigefumi Fukui ◽

Akihiro Tsuji ◽

Norifumi Nakanishi

Keyword(s):

Pulmonary Arterial Hypertension ◽

Combination Therapy ◽

Arterial Hypertension ◽

Receptor Antagonist ◽

Endothelin Receptor ◽

Prostacyclin Analogue ◽

Pulmonary Arterial ◽

Long Acting ◽

Heritable Pulmonary Arterial Hypertension ◽

Phosphodiesterase 5

Download Full-text

Efficacy of Oral Tadalafil, a New Long-acting Phosphodiesterase-5 Inhibitor, for the Short-term Treatment of Pulmonary Arterial Hypertension in a Dog

Journal of Veterinary Medicine Series A ◽

10.1111/j.1439-0442.2006.00800.x ◽

2006 ◽

Vol 53 (3) ◽

pp. 129-133 ◽

Author(s):

F. Serres ◽

A. P. Nicolle ◽

R. Tissier ◽

V. Gouni ◽

J.-L. Pouchelon ◽

...

Keyword(s):

Pulmonary Arterial Hypertension ◽

Arterial Hypertension ◽

Term Treatment ◽

Short Term Treatment ◽

Phosphodiesterase 5 Inhibitor ◽

Pulmonary Arterial ◽

Long Acting ◽

Phosphodiesterase 5

Download Full-text

Faculty Opinions recommendation of Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.737062714.793568475 ◽

2019 ◽

Author(s):

Todd Bull

Keyword(s):

Pulmonary Arterial Hypertension ◽

Connective Tissue ◽

Arterial Hypertension ◽

Connective Tissue Disease ◽

Case Series ◽

Phosphodiesterase 5 Inhibitor ◽

Pulmonary Arterial ◽

Phosphodiesterase 5

Download Full-text

ADVERSE EFFECTS OF ENDOTHELIN RECEPTOR ANTAGONIST AND PHOSPHODIESTERASE-5 INHIBITOR COMBINATION THERAPY IN PULMONARY ARTERIAL HYPERTENSION: A SYSTEMATIC REVIEW AND META-ANALYSIS

CHEST Journal ◽

10.1016/j.chest.2020.05.397 ◽

2020 ◽

Vol 157 (6) ◽

pp. A327

Author(s):

S. Shivakumar ◽

L. Mohammadi ◽

A. Mangoni

Keyword(s):

Systematic Review ◽

Pulmonary Arterial Hypertension ◽

Adverse Effects ◽

Combination Therapy ◽

Arterial Hypertension ◽

Meta Analysis ◽

Endothelin Receptor ◽

Pulmonary Arterial ◽

Phosphodiesterase 5 ◽

Inhibitor Combination

Download Full-text

Effect of Combination Therapy of Endothelin Receptor Antagonist and Phosphodiesterase-5 Inhibitor on Clinical Outcome and Pulmonary Haemodynamics in Patients with Pulmonary Arterial Hypertension: A Meta-Analysis

Clinical Drug Investigation ◽

10.1007/s40261-019-00841-1 ◽

2019 ◽

Vol 39 (11) ◽

pp. 1031-1044 ◽

Author(s):

Lopamudra Kirtania ◽

Rituparna Maiti ◽

Anand Srinivasan ◽

Archana Mishra

Keyword(s):

Pulmonary Arterial Hypertension ◽

Combination Therapy ◽

Clinical Outcome ◽

Arterial Hypertension ◽

Receptor Antagonist ◽

Meta Analysis ◽

Endothelin Receptor ◽

Pulmonary Haemodynamics ◽

Pulmonary Arterial ◽

Phosphodiesterase 5

Download Full-text

REPLACE: A prospective, randomized trial of riociguat replacing phosphodiesterase 5 inhibitor therapy in patients with pulmonary arterial hypertension who are not at treatment goal

10.1183/1393003.congress-2017.pa2417 ◽

2017 ◽

Author(s):

Marius M. Hoeper ◽

Hossein-Ardeschir Ghofrani ◽

Raymond L. Benza ◽

Paul A. Corris ◽

JSR. Gibbs ◽

...

Keyword(s):

Pulmonary Arterial Hypertension ◽

Arterial Hypertension ◽

Randomized Trial ◽

Inhibitor Therapy ◽

Treatment Goal ◽

Prospective Randomized Trial ◽

Phosphodiesterase 5 Inhibitor ◽

Pulmonary Arterial ◽

Phosphodiesterase 5

Download Full-text

Tadalafil: A Long-Acting Phosphodiesterase-5 Inhibitor for the Treatment of Pulmonary Arterial Hypertension

Clinical Therapeutics ◽

10.1016/j.clinthera.2011.06.008 ◽

2011 ◽

Vol 33 (8) ◽

pp. 993-1004 ◽

Author(s):

Sally A. Arif ◽

Henry Poon

Keyword(s):

Pulmonary Arterial Hypertension ◽

Arterial Hypertension ◽

Phosphodiesterase 5 Inhibitor ◽

Pulmonary Arterial ◽

Long Acting ◽

Phosphodiesterase 5

Download Full-text

Should oral combination therapy be the standard of care for pulmonary arterial hypertension?

Expert Review of Respiratory Medicine ◽

10.1080/17476348.2020.1722641 ◽

2020 ◽

Vol 14 (4) ◽

pp. 341-343

Author(s):

Aiko Ogawa ◽

Hiromi Matsubara

Keyword(s):

Pulmonary Arterial Hypertension ◽

Combination Therapy ◽

Arterial Hypertension ◽

Standard Of Care ◽

Pulmonary Arterial

Download Full-text